{"disease":{"id":"esophagogastric-junction-carcinoma","name":"esophagogastric junction carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04151524","title":"Classification of Adenocarcinoma of the Esophagogastric Junction","phase":"","overall_status":"UNKNOWN","enrollment_count":1658,"lead_sponsor_name":"St. James's Hospital, Ireland","has_results":false},{"nct_id":"NCT05180734","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":878,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT02564263","title":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":628,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05978050","title":"Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":354,"lead_sponsor_name":"Biotech Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04442984","title":"FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":326,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT07441785","title":"Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"P. Herzen Moscow Oncology Research Institute","has_results":false},{"nct_id":"NCT06162767","title":"Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis","phase":"NA","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06277921","title":"Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"P. Herzen Moscow Oncology Research Institute","has_results":false},{"nct_id":"NCT03139487","title":"A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":176,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT03933449","title":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02559687","title":"Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04423354","title":"A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG","phase":"NA","overall_status":"UNKNOWN","enrollment_count":94,"lead_sponsor_name":"Guangdong Provincial Hospital of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT05163483","title":"Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":87,"lead_sponsor_name":"Ruihua Xu","has_results":false},{"nct_id":"NCT06761846","title":"Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05170503","title":"Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02658214","title":"Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05970627","title":"Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Yu jiren","has_results":false},{"nct_id":"NCT06374888","title":"Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Convalife (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT06482788","title":"Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04341857","title":"PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06044311","title":"Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Sakti Chakrabarti","has_results":false},{"nct_id":"NCT04034251","title":"Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04161781","title":"A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05161572","title":"Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04510285","title":"A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}